Antibody–drug conjugates come of age in oncology

Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic agents, potentially reducing the severity of side effects by preferentially targeting their payload to the tumour site. ADCs are being increasingly used in combination with other age...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Drug discovery 2023-08, Vol.22 (8), p.641-661
Hauptverfasser:	Dumontet, Charles, Reichert, Janice M., Senter, Peter D., Lambert, John M., Beck, Alain
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/153 692/4028/67/1059 Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - adverse effects Biomedical and Life Sciences Biomedicine Biotechnology Cancer Cancer Research Cancer therapies Cytotoxicity Humans Immunoconjugates - pharmacology Immunoconjugates - therapeutic use Life Sciences Medicinal Chemistry Molecular Medicine Monoclonal antibodies Neoplasms - therapy Pharmacology/Toxicology Review Article Tumor Microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!